JP2020022459A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020022459A5 JP2020022459A5 JP2019169775A JP2019169775A JP2020022459A5 JP 2020022459 A5 JP2020022459 A5 JP 2020022459A5 JP 2019169775 A JP2019169775 A JP 2019169775A JP 2019169775 A JP2019169775 A JP 2019169775A JP 2020022459 A5 JP2020022459 A5 JP 2020022459A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- adenovirus
- vector
- transgene
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701161 unidentified adenovirus Species 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161543661P | 2011-10-05 | 2011-10-05 | |
| US61/543,661 | 2011-10-05 | ||
| JP2018137237A JP6970647B2 (ja) | 2011-10-05 | 2018-07-20 | シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018137237A Division JP6970647B2 (ja) | 2011-10-05 | 2018-07-20 | シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020022459A JP2020022459A (ja) | 2020-02-13 |
| JP2020022459A5 true JP2020022459A5 (enExample) | 2020-03-26 |
| JP7394285B2 JP7394285B2 (ja) | 2023-12-08 |
Family
ID=47045181
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014534785A Active JP6757121B2 (ja) | 2011-10-05 | 2012-10-05 | シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法 |
| JP2018137237A Active JP6970647B2 (ja) | 2011-10-05 | 2018-07-20 | シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法 |
| JP2019169775A Active JP7394285B2 (ja) | 2011-10-05 | 2019-09-18 | シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014534785A Active JP6757121B2 (ja) | 2011-10-05 | 2012-10-05 | シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法 |
| JP2018137237A Active JP6970647B2 (ja) | 2011-10-05 | 2018-07-20 | シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9617560B2 (enExample) |
| EP (1) | EP2764014B1 (enExample) |
| JP (3) | JP6757121B2 (enExample) |
| CN (2) | CN103987726B (enExample) |
| BR (1) | BR112014008284A2 (enExample) |
| CA (1) | CA2851251C (enExample) |
| WO (1) | WO2013052832A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6757120B2 (ja) | 2011-10-05 | 2020-09-16 | ジェンヴェック エルエルシー | アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法 |
| IN2014DN03005A (enExample) | 2011-10-05 | 2015-05-08 | Genvec Inc | |
| CN103987726B (zh) | 2011-10-05 | 2017-10-03 | 金维克有限公司 | 猴(大猩猩)腺病毒或腺病毒载体及其使用方法 |
| US9676824B2 (en) * | 2012-05-29 | 2017-06-13 | Genvec, Inc. | Herpes simplex virus vaccine |
| GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
| CA3034124A1 (en) | 2016-08-23 | 2018-03-01 | Glaxosmithkline Biologicals Sa | Fusion peptides with antigens linked to short fragments of invariant chain (cd74) |
| WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
| US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| ES2959811T3 (es) | 2016-12-09 | 2024-02-28 | Glaxosmithkline Biologicals Sa | Construcciones de adenovirus de chimpancé con antígenos de Lyssavirus |
| GB201701239D0 (en) | 2017-01-25 | 2017-03-08 | Glaxosmithkline Biologicals Sa | Novel formulation |
| WO2019016756A1 (en) | 2017-07-21 | 2019-01-24 | Glaxosmithkline Biologicals Sa | ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES |
| MX2020004487A (es) * | 2017-10-31 | 2020-08-13 | Janssen Vaccines & Prevention Bv | Adenovirus y usos de estos. |
| AU2019231652B2 (en) | 2018-03-06 | 2025-05-22 | Precigen, Inc. | Hepatitis B vaccines and uses of the same |
| AU2019231654B2 (en) | 2018-03-06 | 2025-12-11 | Precigen, Inc. | Human papillomavirus vaccines and uses of the same |
| EP3587581A1 (en) | 2018-06-26 | 2020-01-01 | GlaxoSmithKline Biologicals S.A. | Formulations for simian adenoviral vectors having enhanced storage stability |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| US20220403438A1 (en) | 2019-10-08 | 2022-12-22 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| MX2022010936A (es) | 2020-03-05 | 2022-11-16 | Neotx Therapeutics Ltd | ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas. |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN112220921B (zh) * | 2020-08-25 | 2022-08-16 | 北京交通大学 | 一种针对呼吸道合胞病毒感染的组合疫苗 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| ES2310924T3 (es) | 1993-07-13 | 2009-01-16 | Centelion | Vectores adenovirales defectivos y utilizacion en terapia genica. |
| WO1995016772A1 (en) | 1993-12-14 | 1995-06-22 | Cornell Research Foundation, Inc. | Adenovirus gene expression system |
| WO1995034671A1 (en) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| EP1445322B2 (en) | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| AU2249097A (en) | 1996-01-29 | 1997-08-20 | Georgetown University | Malaria vaccine based upon the addition of a msa1 peptide |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| AU2001234981A1 (en) | 2000-02-09 | 2001-08-20 | Genvec, Inc. | Adenoviral capsid containing chimeric protein ix |
| US6821519B2 (en) | 2000-06-29 | 2004-11-23 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| US6682929B2 (en) | 2001-07-23 | 2004-01-27 | Genvec, Inc. | Adenovector complementing cells |
| AU2002327380A1 (en) | 2001-07-23 | 2003-03-18 | Genvec, Inc. | Cells and methods for propagating adenoviral vectors |
| US6677156B2 (en) | 2001-07-23 | 2004-01-13 | Genvec, Inc. | Non-adenoviral gene product-based complementing cells for adenoviral vectors |
| EP1425045A4 (en) | 2001-09-13 | 2004-11-10 | Genvec Inc | ADENOVIRAL VECTOR AND RELEVANT SYSTEM AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| WO2005075506A1 (en) | 2004-01-09 | 2005-08-18 | The Scripps Research Institute | Identification of endogenous trimerization domains in the adenovirus fiber protein that allow detargeting and retargeting of viral vectors |
| JP4621743B2 (ja) | 2004-12-13 | 2011-01-26 | カンジ，インコーポレイテッド | 複製欠損アデノウイルスの産生のための細胞株 |
| DE102005006388A1 (de) * | 2005-02-11 | 2006-08-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Replikationsdefiziente RNA-Viren als Impfstoffe |
| WO2007027860A2 (en) | 2005-08-31 | 2007-03-08 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| WO2007073513A2 (en) | 2005-11-10 | 2007-06-28 | Genvec, Inc. | Method for propagating adenoviral vectors encoding inhibitory gene products |
| CA2658484A1 (en) | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
| DK2350269T3 (en) | 2008-10-31 | 2015-12-07 | Univ Pennsylvania | ABE ADENOVIRUS WITH SADV-46 HEXONCAPSIDE PROTEINS AND APPLICATIONS THEREOF |
| MX2011007980A (es) | 2009-02-02 | 2011-08-17 | Okairos Ag | Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas. |
| US8865182B2 (en) | 2009-07-31 | 2014-10-21 | Paxvax, Inc. | Adenoviral-based vectors |
| JP5980117B2 (ja) * | 2009-11-09 | 2016-08-31 | ジェンヴェック，インコーポレーテッド | サルアデノウイルスベクターの増殖方法 |
| US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
| WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
| CN103987726B (zh) | 2011-10-05 | 2017-10-03 | 金维克有限公司 | 猴(大猩猩)腺病毒或腺病毒载体及其使用方法 |
| WO2013052859A2 (en) * | 2011-10-05 | 2013-04-11 | Genvec, Inc. | Adenoviral vector-based respiratory syncytial virus (rsv) vaccine |
| IN2014DN03005A (enExample) | 2011-10-05 | 2015-05-08 | Genvec Inc | |
| JP6757120B2 (ja) | 2011-10-05 | 2020-09-16 | ジェンヴェック エルエルシー | アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法 |
| EP2809346A1 (en) * | 2012-02-02 | 2014-12-10 | GenVec, Inc. | Adenoviral vector-based malaria vaccine |
| US9676824B2 (en) | 2012-05-29 | 2017-06-13 | Genvec, Inc. | Herpes simplex virus vaccine |
-
2012
- 2012-10-05 CN CN201280059662.5A patent/CN103987726B/zh active Active
- 2012-10-05 US US14/349,470 patent/US9617560B2/en active Active
- 2012-10-05 WO PCT/US2012/059006 patent/WO2013052832A2/en not_active Ceased
- 2012-10-05 CN CN201710795518.2A patent/CN107574154A/zh active Pending
- 2012-10-05 BR BR112014008284-7A patent/BR112014008284A2/pt not_active Application Discontinuation
- 2012-10-05 CA CA2851251A patent/CA2851251C/en active Active
- 2012-10-05 JP JP2014534785A patent/JP6757121B2/ja active Active
- 2012-10-05 EP EP12775113.9A patent/EP2764014B1/en active Active
-
2017
- 2017-04-10 US US15/482,991 patent/US10059962B2/en active Active
-
2018
- 2018-07-20 JP JP2018137237A patent/JP6970647B2/ja active Active
- 2018-07-24 US US16/043,501 patent/US10787682B2/en active Active
-
2019
- 2019-09-18 JP JP2019169775A patent/JP7394285B2/ja active Active
-
2020
- 2020-08-25 US US17/002,064 patent/US11359214B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020022459A5 (enExample) | ||
| JP2018520997A5 (enExample) | ||
| JP2010227108A5 (enExample) | ||
| JP2021112211A5 (enExample) | ||
| JP2019214579A5 (enExample) | ||
| JP2010065037A5 (enExample) | ||
| JP2002524024A5 (enExample) | ||
| JP2020505025A5 (enExample) | ||
| JP2016537341A5 (enExample) | ||
| JP2019522461A5 (enExample) | ||
| JP2012505657A5 (enExample) | ||
| JP2019528793A5 (enExample) | ||
| JP2016501531A5 (enExample) | ||
| JP2016146837A5 (enExample) | ||
| JP2011087580A5 (enExample) | ||
| JP2003514526A5 (enExample) | ||
| JP2017534262A5 (enExample) | ||
| JP2013539454A5 (enExample) | ||
| JP2017532302A5 (enExample) | ||
| JP2010534684A5 (enExample) | ||
| JP2008525033A5 (enExample) | ||
| JP2019524140A5 (enExample) | ||
| RU2019144161A (ru) | Последовательности нуклеиновых кислот и аминокислотные последовательности аденовирусов человекообразных обезьян, исключая человека, содержащие их векторы и их применения | |
| RU2015135890A (ru) | Композиция вакцины | |
| JP2015533791A5 (enExample) |